Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Return on Sales (2023 - 2025)

Historic Return on Sales for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 4.46%.

  • BioLineRx's Return on Sales fell 37000.0% to 4.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.09%, marking a year-over-year increase of 5000.0%. This contributed to the annual value of 0.67% for FY2024, which is 99300.0% up from last year.
  • Latest data reveals that BioLineRx reported Return on Sales of 4.46% as of Q3 2025, which was down 37000.0% from 6.67% recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Return on Sales ranged from a high of 15.06% in Q1 2023 and a low of 17.17% during Q4 2023
  • Its 3-year average for Return on Sales is 3.74%, with a median of 2.61% in 2025.
  • Data for BioLineRx's Return on Sales shows a peak YoY increase of 164900bps (in 2024) and a maximum YoY decrease of -156300bps (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows BioLineRx's Return on Sales stood at 17.17% in 2023, then surged by 96bps to 0.68% in 2024, then tumbled by -560bps to 4.46% in 2025.
  • Its last three reported values are 4.46% in Q3 2025, 6.67% for Q2 2025, and 7.73% during Q1 2025.